These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 1386485)

  • 1. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus.
    Layne SP; Merges MJ; Dembo M; Spouge JL; Conley SR; Moore JP; Raina JL; Renz H; Gelderblom HR; Nara PL
    Virology; 1992 Aug; 189(2):695-714. PubMed ID: 1386485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.
    Moore JP; McKeating JA; Huang YX; Ashkenazi A; Ho DD
    J Virol; 1992 Jan; 66(1):235-43. PubMed ID: 1727487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.
    McKeating JA; McKnight A; Moore JP
    J Virol; 1991 Feb; 65(2):852-60. PubMed ID: 1898972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4.
    Moore JP; McKeating JA; Norton WA; Sattentau QJ
    J Virol; 1991 Mar; 65(3):1133-40. PubMed ID: 1995942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4.
    Orloff SL; Kennedy MS; Belperron AA; Maddon PJ; McDougal JS
    J Virol; 1993 Mar; 67(3):1461-71. PubMed ID: 8437224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of infectivity by progeny virus from alpha interferon-treated human immunodeficiency virus type 1-infected T cells is associated with defective assembly of envelope gp120.
    Hansen BD; Nara PL; Maheshwari RK; Sidhu GS; Bernbaum JG; Hoekzema D; Meltzer MS; Gendelman HE
    J Virol; 1992 Dec; 66(12):7543-8. PubMed ID: 1279206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies.
    Poignard P; Moulard M; Golez E; Vivona V; Franti M; Venturini S; Wang M; Parren PW; Burton DR
    J Virol; 2003 Jan; 77(1):353-65. PubMed ID: 12477840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced HIV infectivity and changes in GP120 conformation associated with viral incorporation of human leucocyte antigen class I molecules.
    Cosma A; Blanc D; Braun J; Quillent C; Barassi C; Moog C; Klasen S; Spire B; Scarlatti G; Pesenti E; Siccardi AG; Beretta A
    AIDS; 1999 Oct; 13(15):2033-42. PubMed ID: 10546855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1.
    Willey RL; Martin MA; Peden KW
    J Virol; 1994 Feb; 68(2):1029-39. PubMed ID: 7904656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor.
    Dey B; Del Castillo CS; Berger EA
    J Virol; 2003 Mar; 77(5):2859-65. PubMed ID: 12584309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4-IgG binding threshold for inactivation of human immunodeficiency virus type 1.
    Berkower I; Mostowski H; Bull TE; Murphy D
    J Infect Dis; 1996 Apr; 173(4):863-9. PubMed ID: 8603964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymerase chain reaction-based assay for antibody-mediated neutralization of HIV-1 reveals a population of nonneutralized virus undetected by conventional p24 assay.
    Achkar JM; Wang XH; Nyambi P; Gorny MK; Zolla-Pazner S; Bandrés JC
    J Acquir Immune Defic Syndr; 2000 Jul; 24(3):203-10. PubMed ID: 10969343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphometric analysis of envelope glycoprotein gp120 distribution on HIV-1 virions.
    Hart TK; Klinkner AM; Ventre J; Bugelski PJ
    J Histochem Cytochem; 1993 Feb; 41(2):265-71. PubMed ID: 7678271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physicochemical dissociation of CD4-mediated syncytium formation and shedding of human immunodeficiency virus type 1 gp120.
    Fu YK; Hart TK; Jonak ZL; Bugelski PJ
    J Virol; 1993 Jul; 67(7):3818-25. PubMed ID: 8510207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core.
    Hammonds J; Chen X; Ding L; Fouts T; De Vico A; zur Megede J; Barnett S; Spearman P
    Virology; 2003 Sep; 314(2):636-49. PubMed ID: 14554091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking of human immunodeficiency virus infection depends on cell density and viral stock age.
    Layne SP; Merges MJ; Spouge JL; Dembo M; Nara PL
    J Virol; 1991 Jun; 65(6):3293-300. PubMed ID: 1674549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures.
    O'Brien WA; Mao SH; Cao Y; Moore JP
    J Virol; 1994 Aug; 68(8):5264-9. PubMed ID: 8035523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.
    Chertova E; Bess JW; Crise BJ; Sowder II RC; Schaden TM; Hilburn JM; Hoxie JA; Benveniste RE; Lifson JD; Henderson LE; Arthur LO
    J Virol; 2002 Jun; 76(11):5315-25. PubMed ID: 11991960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
    Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor.
    Brighty DW; Rosenberg M; Chen IS; Ivey-Hoyle M
    Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7802-5. PubMed ID: 1909031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.